GHRP-2 vs Wolverine Stack
Well Studied vs Well Studied
synergistic Mechanism-based · 47% GHRP-2 and Wolverine Stack work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
GHRP-2 Wolverine Stack
Weight 817.9 Da N/A
Half-life ~30 minutes —
Chain 6 amino acids N/A
Type Synthetic hexapeptide Peptide blend
Key Benefits
GHRP-2
01 Potent stimulation of natural growth hormone release
02 Enhanced muscle growth and recovery
03 Improved body composition and fat metabolism
04 Better sleep quality and recovery
05 Increased appetite (can be beneficial for bulking)
06 Maintains natural GH pulsatile release patterns
07 Synergistic effects when combined with GHRH peptides
Wolverine Stack
01 Complementary healing mechanisms
02 87.5% improvement in knee pain patients
03 Reduced inflammation and enhanced cell migration
04 Promotes angiogenesis and reduces scarring
Dosing Protocols
GHRP-2
100-300 mcg / 2-3x daily
GH optimization 100-150 mcg 2-3x daily
Enhanced results 200-300 mcg 2-3x daily
With GHRH (synergy) 100 mcg each 2-3x daily
Pre-sleep protocol 100-200 mcg Before bed
Wolverine Stack
BPC-157: 250-500 mcg per dose + TB-500: 2-2.5 mg per dose / BPC-157: 1-2x daily; TB-500: 2x per week (typically Monday/Thursday or Tuesday/Friday)
General Recovery Protocol BPC-157: 250mcg 2x/day + TB-500: 2mg 2x/week BPC-157 daily, TB-500 twice weekly
Intensive Injury Recovery BPC-157: 500mcg 2x/day + TB-500: 2.5mg 2x/week BPC-157 daily, TB-500 twice weekly
Maintenance/Prevention Protocol BPC-157: 250mcg 1x/day + TB-500: 2mg 1x/week BPC-157 daily, TB-500 weekly
Side Effects
GHRP-2
Increased appetite (less than GHRP-6)
Mild water retention
Tingling or numbness in extremities
Tiredness or lethargy after injection
Mild headache
Wolverine Stack
Not extensively documented in human studies
Generally well-tolerated in available research
Contraindications
Active cancer or history of cancer
Pregnancy or breastfeeding
Pituitary disorders
Diabetic retinopathy
WADA prohibited for competitive athletes
ANY history of cancer or suspicious growths
Active malignancy or concurrent chemotherapy
Pregnancy or breastfeeding
Research Evidence
GHRP-2 Wolverine Stack
Status Well Studied Well Studied
References 3 studies 6 studies
Latest — 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.